Luye Pharma Group (SEHK:2186) - Hisse Senedi Fiyatı, Haberler ve Analizler

2186 Stoklara Genel Bakış

Bir yatırım holding şirketi olan Luye Pharma Group Ltd. dünya çapında farmasötik ürünler geliştirmekte, üretmekte, pazarlamakta ve satmaktadır. Daha fazla detay

2186 temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	4/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Kazançların yılda 21.95% oranında artması öngörülüyor

Kazançlar geçen yıl 68.3% oranında arttı

Analistler hisse senedi fiyatının 35.9% oranında artacağı konusunda hemfikir

Risk Analizi

Risk kontrollerimizden 2186 için herhangi bir risk tespit edilmedi.

Luye Pharma Group Ltd. Rakipler

Shandong Xinhua Pharmaceutical

SEHK:719

HK$9.6b

SSY Group

SEHK:2005

HK$11.2b

China Traditional Chinese Medicine Holdings

SEHK:570

HK$11.6b

Consun Pharmaceutical Group

SEHK:1681

HK$7.0b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Luye Pharma Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$2.68
52 Haftanın En Yüksek Seviyesi	HK$4.00
52 Haftanın En Düşük Seviyesi	HK$2.34
Beta	0.85
11 Aylık Değişim	-16.25%
3 Aylık Değişim	-5.30%
1 Yıllık Değişim	-31.28%
33 Yıllık Değişim	-27.96%
5 Yıllık Değişim	-57.46%
Halka arzdan bu yana değişim	-60.00%

Son Haberler & Güncellemeler

Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Sep 25

Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Aug 29

Recent updates

Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Sep 25

Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Aug 29

Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

Jun 19

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

May 21

Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Aug 17

Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

May 10

We Think Luye Pharma Group (HKG:2186) Is Taking Some Risk With Its Debt

Sep 20

Time To Worry? Analysts Just Downgraded Their Luye Pharma Group Ltd. (HKG:2186) Outlook

Apr 06

Luye Pharma Group's (HKG:2186) Shareholders Are Down 31% On Their Shares

Mar 17

Hissedar Getirileri

	2186	HK Pharmaceuticals	HK Pazar
7D	-5.6%	-2.0%	-2.7%
1Y	-31.3%	-9.4%	10.9%

Getiri vs. Endüstri: 2186 geçen yıl % -9.4 oranında getiri sağlayan Hong Kong Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: 2186 geçen yıl % 10.9 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 2186's price volatile compared to industry and market?
2186 volatility
2186 Average Weekly Movement	4.9%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	9.0%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.2%

İstikrarlı Hisse Senedi Fiyatı: 2186 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 2186 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1994	5,234	Dian Bo Liu	www.luye.cn

Bir yatırım holding şirketi olan Luye Pharma Group Ltd. dünya çapında farmasötik ürünler geliştirmekte, üretmekte, pazarlamakta ve satmaktadır. Şirket, yumurtalık kanseri ve yumurtalık karsinomu için Lipusu; kanser radyoterapisi için kimyasal bir hassaslaştırıcı olan CMNa; yumurtalık veya küçük hücreli olmayan akciğer kanseri için Tiandida; çeşitli kanser türlerinin tedavisi için bir enjeksiyon olan Boyounuo ve hiperkolesterolemi tedavisi için lipit düzenleyici bir ilaç olan Xuezhikang'ı sunmaktadır.

Luye Pharma Group Ltd. Temel Bilgiler Özeti

Luye Pharma Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
2186 temel i̇stati̇sti̇kler
Piyasa değeri	HK$10.08b
Kazançlar(TTM)	HK$829.72m
Gelir(TTM)	HK$6.80b

12.2x

F/K Oranı

1.5x

P/S Oranı

2186 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
2186 gelir tablosu (TTM)
Gelir	CN¥6.31b
Gelir Maliyeti	CN¥1.97b
Brüt Kâr	CN¥4.34b
Diğer Giderler	CN¥3.57b
Kazançlar	CN¥770.46m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.20
Brüt Marj	68.73%
Net Kâr Marjı	12.20%
Borç/Özkaynak Oranı	66.6%

2186 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

2186 Stoklara Genel Bakış

Ödüller

Risk Analizi

Luye Pharma Group Ltd. Rakipler

SEHK:719

HK$9.6b

SEHK:2005

HK$11.2b

SEHK:570

HK$11.6b

SEHK:1681

HK$7.0b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Consensus EPS estimates increase by 24%, revenue downgraded

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Recent updates

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Unpleasant Surprises Could Be In Store For Luye Pharma Group Ltd.'s (HKG:2186) Shares

Consensus EPS estimates increase by 24%, revenue downgraded

First half 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.041 in 1H 2023)

Does Luye Pharma Group (HKG:2186) Have A Healthy Balance Sheet?

Luye Pharma Group Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Luye Pharma Announces U.S. FDA Approval of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for Treating Schizophrenia and Schizoaffective Disorder

Shenzhen Luye Private Equity Investment Fund Partnership (Limited Partnership) managed by Shenzhen Investment Holding Capital Co., Ltd. agreed to acquire 25% stake in Nanjing Luye Pharmaceutical Co., Ltd. from Luye Pharma Group Ltd. (SEHK:2186) for CNY 1.0 billion.

Luye Pharma Group Ltd. Announces Approval of New Analgesic Product Mimeixin (Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-Release Tablets) for Marketing in China

Luye Pharma Group Ltd.'s (HKG:2186) Earnings Haven't Escaped The Attention Of Investors

Luye Pharma Group Ltd. Announces Approval of Meibirui (Paliperidone Palmitate Injection) for Marketing in China

We Discuss Why Luye Pharma Group Ltd.'s (HKG:2186) CEO Compensation May Be Closely Reviewed

Here's Why Luye Pharma Group (HKG:2186) Has A Meaningful Debt Burden

Now 20% overvalued

Now 23% overvalued

Full year 2023 earnings: EPS misses analyst expectations

Luye Pharma Group Ltd., Annual General Meeting, May 28, 2024

Luye Pharma Group Ltd. to Report Fiscal Year 2023 Results on Mar 27, 2024

Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao

Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610

Is Luye Pharma Group Ltd. (HKG:2186) Trading At A 27% Discount?

Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension (Ly03010) in the United States

Now 20% undervalued after recent price drop

Some Confidence Is Lacking In Luye Pharma Group Ltd.'s (HKG:2186) P/S

Investor sentiment deteriorates as stock falls 17%

Luye Pharma Group (HKG:2186) Takes On Some Risk With Its Use Of Debt

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong

Luye Pharma Group Ltd. Announces Board Changes

A Look At The Fair Value Of Luye Pharma Group Ltd. (HKG:2186)

Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 16%

Is Luye Pharma Group (HKG:2186) A Risky Investment?

Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio

First half 2023 earnings released: EPS: CN¥0.041 (vs CN¥0.085 in 1H 2022)

Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin

Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States

Luye Pharma Group Ltd.'s (HKG:2186) Intrinsic Value Is Potentially 20% Below Its Share Price

Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in China

Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation Therapy

Luye Pharma Group Ltd. Announces Marketing Registration of Xuezhikang Approved in Uzbekistan

Luye Pharma Group Ltd Announces Acceptance of the NDA for Lurbinectedin by NMPA in China

Luye Pharma Group Ltd. Appoints XIA Lian as an Independent Non-Executive Director

Is Luye Pharma Group (HKG:2186) Using Too Much Debt?

Consensus EPS estimates fall by 11%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Luye Pharma Group Ltd. Announces Approval Obtained for Initiating Clinical Trial in China for the 3-Month Dosing Form of Goserelin Acetate Extended-Release Microspheres for Injection (LY01022)

FDA Approves Luye Pharma's Rykindo for the Treatment of Schizophrenia and Bipolar 1 Disorder

Luye Pharma Group Ltd. Announces the Acceptance of Marketing Application of Paliperidone Palmitate Injection (LY03010)

Luye Pharma Group Ltd. Announces First Patient Dosed in Phase II Clinical Study in China for New Class 1 Drug LY03014

Luye Pharma Group Ltd. Announces the Pivotal Study Conducted in the U.S. in Respect of the Group's New Product Candidate

Less than half of directors are independent

Luye Pharma Group Ltd. Announces Marketing Registration of Class 1 Innovative Antidepressant Ruoxinlin (Ly03005) Approved by NMPA

Luye Pharma Group Ltd. announced that it expects to receive CNY 300 million in funding

First half 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.11 in 1H 2021)

Luye Pharma Group Ltd. to Report Q2, 2022 Results on Aug 29, 2022

Luye Pharma Group Ltd. Announces New Drug Application for New Indication of Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for Breast Cancer Has Been Accepted in China

Luye Pharma Group Ltd. Announces Phase III Clinical Trial of Rotigotine

Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin (LY01017) Approves for Urgent Clinical Use in Hainan